# Harbinger Ventures

> Harbinger Ventures is a VC fund in Cupertino backing Software and Health Care. See 38 investments, check sizes, portfolio and contact details. Updated Aug 2026.

- Type: VC Fund
- Location: Cupertino, United States
- Total investments: 38
- Last investment: Oct 2025
- Lead investor: 13%
- Fund size: $22M
- Last fund: Jul 2019
- Last updated: Aug 2026
- Website: http://www.harbingervc.com

Harbinger Ventures is a VC fund in Cupertino focused on Software and Health Care. Harbinger's mission is to be a value-added venture investor in the core technologies that will enhance the productivity and experience at the workplace or at home. Leveraging the MiTAC-SYNNEX Group's strong financial backing and web of networks, they strive to create synergy and forge strategic relationships among their investee companiesand the Group's affiliated companies at every opportunity. Welcoming challenge, Harbinger will continue to be a forerunner in the technologies that will change the communications and computing networks of tomorrow while generating tangible results and real value for both its investees and investors.

## Contacts

5 contacts available for Harbinger Ventures. Shizune tracks 7 team members at Harbinger Ventures. Sign up free to unlock them: https://app.shizune.co/sign-up/investor-profiles/find-team-emails/harbinger-ventures?utm_source=investor_profile

## Round sizes

| Stage | Round size |
| --- | --- |
| Series A | $5.4M–$11M |
| Series B | $8M–$27M |
| Series C | $12M–$30M |

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Software | 6 | 16% |
| Health Care | 6 | 16% |
| Manufacturing | 6 | 16% |
| Semiconductor | 5 | 13% |
| Medical | 4 | 11% |

57 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series A | 12 | 32% |
| Series B | 8 | 21% |
| Series C | 6 | 16% |
| Funding Round | 5 | 13% |
| Series D | 3 | 8% |

7 stages tracked in total.

### Country

| Country | Investments | Share |
| --- | --- | --- |
| United States | 20 | 53% |
| China | 6 | 16% |
| Taiwan | 2 | 5% |
| Canada | 1 | 3% |

## Team

| Name | Title | Investments | Profile |
| --- | --- | --- | --- |
| T.C. Chou | President, Harbinger Taiwan | 1 | https://shizune.co/investors/profile/t-c-chou |
| John Tzeng | VP, Harbinger Taiwan | 0 | https://shizune.co/investors/profile/john-tzeng |
| Matthew Miau | Chairman of Harbinger, Taiwan | 0 | https://shizune.co/investors/profile/matthew-miau |
| M.R. Lin | Venture Partner | 0 | https://shizune.co/investors/profile/m-r-lin |
| Ronald Han | VP | 0 | https://shizune.co/investors/profile/ronald-han |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| xMEMS | xMEMS designs solutions and applications by integrating smart methodologies for a range of consumer electronics devices. The company was founded in 2018 and is headquartered in Santa Clara, California, United States. | $21M | Series D | Oct 30, 2025 |  |
| DOTDOT | Dotdot Global develops Line Smart solutions for retail, food, hotels, and shopping malls. | $4.4M | Series A | Sep 26, 2024 |  |
| Profet AI | Profet AI is a software solution company that offers AI and machine learning automation solutions designed for manufacturing companies. | $5.6M | Series A | Jan 04, 2023 |  |
| CotheraBio | CotheraBio develops innovative cancer therapies with a focus on translational oncology. It has developed its proprietary i-CR® technology platform, which is a powerful method for providing individualized drug screening and new drug development. The platform combines a high content screening system with the conditional reprogramming of primarycultured tumor cells, which enables the efficient and undifferentiated expansion of primary patient-derived tumor cells in vitro, while also preserving the tumor’s heterogeneity. |  | Venture - Series Unknown | Jan 02, 2021 |  |
| Cora | Cora is an organic tampon and elegant accessories company that produces and markets applicator tampons, sanitary pads, and necklaces. The company believes that time of the month should never be a source of shame, harm, or uncertainty. (Also: excessively pink packaging.) And it should never keep a girl from getting her education. They are committedto giving all women access to safe and effective period products as well as valuable and trustworthy information to educate and empower. Cora creates fearless content and innovative products through an elevated brand to shift the way women perceive and manage their periods, bladder leaks, post-birth recovery, and other natural experiences. Organic tampons, elegant accessories, convenient delivery, and period products to girls in need for every box sold. | $7.5M | Series A | Apr 02, 2019 |  |
| Vinebox | VINEBOX is the first monthly wine-by-the-glass membership club. Explore 3 curated wines in perfectly measured pours each month. | $5.9M | Series A | Jan 19, 2019 |  |
| Cora | Cora is an organic tampon and elegant accessories company that produces and markets applicator tampons, sanitary pads, and necklaces. The company believes that time of the month should never be a source of shame, harm, or uncertainty. (Also: excessively pink packaging.) And it should never keep a girl from getting her education. They are committedto giving all women access to safe and effective period products as well as valuable and trustworthy information to educate and empower. Cora creates fearless content and innovative products through an elevated brand to shift the way women perceive and manage their periods, bladder leaks, post-birth recovery, and other natural experiences. Organic tampons, elegant accessories, convenient delivery, and period products to girls in need for every box sold. | $6M | Series A | Nov 06, 2017 |  |
| Eureka Therapeutics | Eureka Therapeutics is a biotechnology company that focuses on immunotherapies for the treatment of cancer. The company's platform is a novel T-cell therapy construct that mimics the natural biology of T-cells to fight cancer. It utilizes a paradigm-changing technology platform to develop fully-human antibodies against intracellular cancerantigens.Eureka Therapeutics was founded in 2006 and is headquartered in Emeryville, California. | $21M | Series C | Sep 23, 2014 |  |
| Coda Automotive | Coda Automotive builds eco-friendly transportation -- chiefly electric cars -- to create a livable future for generations to come. Headquartered in Southern California, CODA Automotive teamed with American partners to develop an American designed and manufactured electric drivetrain as well as battery system electronics to serve as thefoundation for the CODA car. They also partnered with the most highly proficient and advanced companies from around the world, from China to Europe, to build a safe and affordable all-electric car. All the while, CODA Automotive maintained control of brand, design, and critical intellectual property. | $76M | Series D | Jan 05, 2011 |  |
| Envivio | Envivio (NASDAQ: ENVI) is a leader in software-based solutions for multi-screen video processing and delivery. Envivio solutions remove the boundaries of traditional television and make the world’s video content universally enjoyable by all viewers, on any device, across any network, at any time. Now in its second decade of developingmarket-leading video convergence solutions, Envivio powers services for more than 300 content and service provider customers around the world, including eight of the top 10 mobile operators, nine of the top 10 broadband providers and three of the top four US cable operators. Envivio is headquartered in South San Francisco, California and has offices worldwide including France, England, China, Singapore and Japan. Visit www.envivio.com for more information. | $1M | Debt Financing | Dec 31, 2009 |  |

10 of 38 investments shown.

## Co-investors
- [Sycamore Ventures](https://shizune.co/investors/profile/sycamore-ventures) — VC Fund, 5 deals together
- [WI Harper Group](https://shizune.co/investors/profile/wi-harper-group) — VC Fund, 5 deals together
- [Acorn Campus Ventures](https://shizune.co/investors/profile/acorn-campus-ventures) — VC Fund, 3 deals together
- [Crescendo Ventures](https://shizune.co/investors/profile/crescendo-ventures) — VC Fund, 3 deals together
- [H&Q Asia Pacific](https://shizune.co/investors/profile/h-a-asia-pacific) — VC Fund, 3 deals together
- [Innovacom](https://shizune.co/investors/profile/innovacom) — VC Fund, 3 deals together

## Similar investors

### Similar industry
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [Right Side Capital Management](https://shizune.co/investors/profile/right-side-capital-management) — VC Fund

### Similar stage
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund

### Similar country
- [National Development Fund of Taiwan Government](https://shizune.co/investors/profile/national-development-fund-of-taiwan-government) — VC Fund
- [Darwin Venture Management](https://shizune.co/investors/profile/darwin-venture-management) — VC Fund
- [AVA Angels](https://shizune.co/investors/profile/ava-angels) — VC Fund

## Featured in investor lists
- [Artificial intelligence VC Funds in Taiwan](https://shizune.co/investors/artificial-intelligence-vc-funds-taiwan)
- [Machine Learning Investors in Taiwan](https://shizune.co/investors/machine-learning-investors-taiwan)

## FAQ

### What does Harbinger Ventures invest in?

Harbinger Ventures invests primarily in Software, Health Care and Manufacturing startups, most often at Series A and Series B stage. Most of the 38 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### What is Harbinger Ventures's check size?

Harbinger Ventures typically joins rounds of $5.4M–$11M at Series A, $8M–$27M at Series B and $12M–$30M at Series C. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds Harbinger Ventures participates in.

### How do I contact Harbinger Ventures?

Public channels for Harbinger Ventures include the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.

### Who are the partners at Harbinger Ventures?

The team at Harbinger Ventures includes T.C. Chou (President, Harbinger Taiwan), John Tzeng (VP, Harbinger Taiwan) and Matthew Miau (Chairman of Harbinger, Taiwan), among 7 team members tracked by Shizune. The Team section lists each member with their title, investment count and links.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co